Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:BBIO NASDAQ:BEAM NASDAQ:LNTH NASDAQ:ROIV On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBBIOBridgeBio Pharma$54.26+0.8%$52.42$21.72▼$57.49$10.29B1.361.79 million shs1.49 million shsBEAMBeam Therapeutics$27.96-0.9%$22.45$13.52▼$35.25$2.85B2.252.57 million shs1.55 million shsLNTHLantheus$56.06-0.8%$54.14$47.25▼$118.21$3.84B0.091.49 million shs651,643 shsROIVRoivant Sciences$18.22+0.6%$14.60$8.73▼$18.42$12.37B1.27.64 million shs6.95 million shsA Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for November 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBBIOBridgeBio Pharma+0.84%-1.20%+7.13%+17.19%+121.92%BEAMBeam Therapeutics-0.85%+7.62%+18.52%+28.73%+28.14%LNTHLantheus-0.80%+0.83%+5.32%-23.13%-49.33%ROIVRoivant Sciences+0.55%+5.56%+23.95%+57.75%+56.80%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBBIOBridgeBio Pharma$54.26+0.8%$52.42$21.72▼$57.49$10.29B1.361.79 million shs1.49 million shsBEAMBeam Therapeutics$27.96-0.9%$22.45$13.52▼$35.25$2.85B2.252.57 million shs1.55 million shsLNTHLantheus$56.06-0.8%$54.14$47.25▼$118.21$3.84B0.091.49 million shs651,643 shsROIVRoivant Sciences$18.22+0.6%$14.60$8.73▼$18.42$12.37B1.27.64 million shs6.95 million shsA Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for November 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBBIOBridgeBio Pharma+0.84%-1.20%+7.13%+17.19%+121.92%BEAMBeam Therapeutics-0.85%+7.62%+18.52%+28.73%+28.14%LNTHLantheus-0.80%+0.83%+5.32%-23.13%-49.33%ROIVRoivant Sciences+0.55%+5.56%+23.95%+57.75%+56.80%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBBIOBridgeBio Pharma 2.88Moderate Buy$65.2520.25% UpsideBEAMBeam Therapeutics 2.94Moderate Buy$45.9264.22% UpsideLNTHLantheus 2.50Moderate Buy$74.5032.89% UpsideROIVRoivant Sciences 2.80Moderate Buy$19.949.43% UpsideCurrent Analyst Ratings BreakdownLatest BEAM, ROIV, LNTH, and BBIO Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails10/24/2025BBIOBridgeBio PharmaWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)10/24/2025BEAMBeam TherapeuticsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)10/21/2025BBIOBridgeBio PharmaRaymond James FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOutperform$56.00 ➝ $59.0010/10/2025BEAMBeam TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$80.0010/9/2025BEAMBeam TherapeuticsJPMorgan Chase & Co.Subscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOverweight$48.00 ➝ $46.0010/9/2025BEAMBeam TherapeuticsJefferies Financial GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageHold ➝ Buy$41.0010/8/2025LNTHLantheusThe Goldman Sachs GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price TargetBuy ➝ Neutral$110.00 ➝ $77.0010/8/2025BBIOBridgeBio PharmaWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)10/8/2025BEAMBeam TherapeuticsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)10/8/2025LNTHLantheusThe Goldman Sachs GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy ➝ Neutral$110.00 ➝ $77.0010/8/2025LNTHLantheusWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingHold (C-)(Data available from 10/25/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBBIOBridgeBio Pharma$221.90M46.75N/AN/A($7.71) per share-7.04BEAMBeam Therapeutics$63.52M44.53N/AN/A$8.86 per share3.16LNTHLantheus$1.52B2.51$7.03 per share7.97$15.65 per share3.58ROIVRoivant Sciences$29.05M428.30N/AN/A$7.45 per share2.45Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBBIOBridgeBio Pharma-$535.76M-$4.09N/AN/AN/A-329.25%N/A-85.69%11/11/2025 (Estimated)BEAMBeam Therapeutics-$376.74M-$4.50N/AN/AN/A-661.31%-43.15%-31.06%11/4/2025 (Estimated)LNTHLantheus$312.44M$3.7614.918.88N/A17.82%34.06%19.10%11/6/2025 (Estimated)ROIVRoivant Sciences-$171.98M-$0.70N/AN/AN/A-2,111.79%-15.90%-14.95%11/11/2025 (Estimated)Latest BEAM, ROIV, LNTH, and BBIO EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails11/11/2025Q3 2025BBIOBridgeBio Pharma-$0.89N/AN/AN/A$107.71 millionN/A11/11/2025Q2 2026ROIVRoivant Sciences-$0.27N/AN/AN/A$6.92 millionN/A11/6/2025Q3 2025LNTHLantheus$1.28N/AN/AN/A$363.42 millionN/A11/4/2025Q3 2025BEAMBeam Therapeutics-$1.03N/AN/AN/A$12.83 millionN/A8/6/2025Q2 2025LNTHLantheus$1.65$1.57-$0.08$1.12$389.69 million$378.05 million8/5/2025Q2 2025BBIOBridgeBio Pharma-$0.83-$0.95-$0.12-$0.95$98.46 million$110.57 million8/5/2025Q2 2025BEAMBeam Therapeutics-$1.04-$1.00+$0.04-$1.00$13.29 million$8.47 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthBBIOBridgeBio PharmaN/AN/AN/AN/AN/ABEAMBeam TherapeuticsN/AN/AN/AN/AN/ALNTHLantheusN/AN/AN/AN/AN/AROIVRoivant SciencesN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBBIOBridgeBio PharmaN/A5.195.08BEAMBeam TherapeuticsN/A6.756.75LNTHLantheus0.494.294.07ROIVRoivant SciencesN/A40.5440.54Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBBIOBridgeBio Pharma99.85%BEAMBeam Therapeutics99.68%LNTHLantheus99.06%ROIVRoivant Sciences64.76%Insider OwnershipCompanyInsider OwnershipBBIOBridgeBio Pharma18.20%BEAMBeam Therapeutics3.50%LNTHLantheus1.50%ROIVRoivant Sciences10.80%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableBBIOBridgeBio Pharma400191.17 million156.38 millionOptionableBEAMBeam Therapeutics510101.16 million97.62 millionOptionableLNTHLantheus70067.99 million66.97 millionOptionableROIVRoivant Sciences860682.88 million609.13 millionOptionableBEAM, ROIV, LNTH, and BBIO HeadlinesRecent News About These CompaniesVIRGINIA RETIREMENT SYSTEMS ET Al Makes New Investment in Roivant Sciences Ltd. $ROIVOctober 24 at 4:42 AM | marketbeat.comPriovant announces positive Phase 3 results for targeted dermatomyositis treatmentOctober 24 at 3:24 AM | ncbiotech.orgNBTS Asset Management Inc. Makes New $348,000 Investment in Roivant Sciences Ltd. $ROIVOctober 22 at 6:57 AM | marketbeat.com162,400 Shares in Roivant Sciences Ltd. $ROIV Purchased by TD Asset Management IncOctober 22 at 3:51 AM | marketbeat.comRoivant Sciences Ltd. (NASDAQ:ROIV) Receives Average Recommendation of "Moderate Buy" from AnalystsOctober 22 at 3:15 AM | americanbankingnews.comRoivant Sciences Ltd. (NASDAQ:ROIV) Given Consensus Rating of "Moderate Buy" by AnalystsOctober 22 at 3:12 AM | marketbeat.comWall Street Has a Mixed Opinion on Roivant Sciences Ltd (ROIV)October 21, 2025 | insidermonkey.comRoivant Sciences (NASDAQ:ROIV) Hits New 12-Month High - What's Next?October 21, 2025 | marketbeat.comInsider Selling: Roivant Sciences (NASDAQ:ROIV) CEO Sells 118,418 Shares of StockOctober 18, 2025 | marketbeat.comRoivant Sciences (NASDAQ:ROIV) CEO Eric Venker Sells 318,282 SharesOctober 18, 2025 | marketbeat.comEric Venker Sells 414,683 Shares of Roivant Sciences (NASDAQ:ROIV) StockOctober 18, 2025 | marketbeat.comRoivant Sciences (NASDAQ:ROIV) CEO Eric Venker Sells 118,418 SharesOctober 18, 2025 | insidertrades.comEric Venker Sells 20,727 Shares of Roivant Sciences (NASDAQ:ROIV) StockOctober 15, 2025 | marketbeat.comEric Venker Sells 104,940 Shares of Roivant Sciences (NASDAQ:ROIV) StockOctober 15, 2025 | marketbeat.comRoivant Sciences (NASDAQ:ROIV) Reaches New 12-Month High - Still a Buy?October 15, 2025 | marketbeat.comRoivant Sciences (NASDAQ:ROIV) CEO Sells $336,813.75 in StockOctober 15, 2025 | insidertrades.comGoldman Sachs Sticks to Their Buy Rating for Roivant Sciences (ROIV)October 10, 2025 | theglobeandmail.comEric Venker Sells 138,602 Shares of Roivant Sciences (NASDAQ:ROIV) StockOctober 9, 2025 | marketbeat.comEric Venker Sells 171,396 Shares of Roivant Sciences (NASDAQ:ROIV) StockOctober 9, 2025 | marketbeat.comEric Venker Sells 355,161 Shares of Roivant Sciences (NASDAQ:ROIV) StockOctober 9, 2025 | marketbeat.comEric Venker Sells 138,602 Shares of Roivant Sciences (NASDAQ:ROIV) StockOctober 9, 2025 | insidertrades.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesSoundHound Breaks Critical Resistance: How High Can It Get Now?By Thomas Hughes | September 28, 2025October’s Top 5 Stocks Poised for Big BreakoutsBy Thomas Hughes | October 1, 2025Datavault AI: The New AI Contender Backed by Big FundingBy Jeffrey Neal Johnson | October 1, 2025Costco Investors Will Get a “Special” Treat for ChristmasBy Thomas Hughes | September 29, 2025Beam Global Gets Buy Rating With 101% Upside PotentialBy Nathan Reiff | September 27, 2025BEAM, ROIV, LNTH, and BBIO Company DescriptionsBridgeBio Pharma NASDAQ:BBIO$54.26 +0.45 (+0.84%) Closing price 10/24/2025 04:00 PM EasternExtended Trading$56.29 +2.03 (+3.74%) As of 10/24/2025 07:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.BridgeBio Pharma, Inc., a commercial-stage biopharmaceutical company, discovers, creates, tests, and delivers transformative medicines to treat patients who suffer from genetic diseases and cancers. Its products in development programs include AG10, a next-generation oral small molecule near-complete TTR stabilizer that is in Phase 3 clinical trial for the treatment of TTR amyloidosis, or transthyretin amyloid cardiomyopathy (ATTR-CM); low-dose infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor, which is in Phase 3 double-blinded, placebo-controlled pivotal study for the treatment option for children with achondroplasia; and BBP-631, an AAV5 gene transfer product candidate that is in Phase 1/2 clinical trial for the treatment of congenital adrenal hyperplasia, or CAH, driven by 21-hydroxylase deficiency, or 21OHD. The company also develops Encaleret, a small molecule antagonist of the calcium sensing receptor, or CaSR, which is in phase 3 clinical trial for treating autosomal dominant hypocalcemia type 1, or ADH1; and BBP-418, a glycosylation substrate pro-drug that is in Phase 3 clinical trial for treating limb-girdle muscular dystrophy type 2I/R9 (LGMD2I/R9). In addition, it engages in developing products for mendelian, oncology, and gene therapy diseases. BridgeBio Pharma, Inc. has license and collaboration agreements with the Leland Stanford Junior University; and Leidos Biomedical Research, Inc. The company was founded in 2015 and is headquartered in Palo Alto, California.Beam Therapeutics NASDAQ:BEAM$27.96 -0.24 (-0.85%) Closing price 10/24/2025 04:00 PM EasternExtended Trading$27.96 +0.00 (+0.02%) As of 10/24/2025 07:54 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Beam Therapeutics Inc., a biotechnology company, engages in the development of precision genetic medicines for patients suffering from serious diseases in the United States. It develops BEAM-101 for the treatment of sickle cell disease or beta-thalassemia; and BEAM-302, a liver-targeting LNP formulation to treat severe alpha-1 antitrypsin deficiency; BEAM-201, an anti-CD7 CAR-T product candidate, which is in Phase 1/2 clinical trials for the treatment of refractory T-cell acute lymphoblastic leukemia/T cell lymphoblastic lymphoma; and BEAM-301, a liver-targeting LNP formulation for the treatment of glycogen storage disease 1a. The company has research collaboration agreement with Pfizer Inc., focus on in vivo base editing programs for targets rare genetic diseases of the liver, muscle, and central nervous system; Apellis Pharmaceuticals to conduct preclinical research on target specific genes within the complement system in various organs, including the eye, liver, and brain; Verve Therapeutics, Inc., for cardiovascular disease treatments; Sana Biotechnology, Inc., to research, develop, and commercialize rights to CRISPR Cas12b for cell therapy programs; and Orbital Therapeutics design RNA for the prevention, treatment or diagnosis of human disease. Beam Therapeutics Inc. was incorporated in 2017 and is based in Cambridge, Massachusetts.Lantheus NASDAQ:LNTH$56.06 -0.45 (-0.80%) Closing price 10/24/2025 04:00 PM EasternExtended Trading$55.83 -0.23 (-0.41%) As of 10/24/2025 04:19 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Lantheus Holdings, Inc. develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer. The company also offers Automated Bone Scan Index that calculates the disease burden of prostate cancer by detecting and classifying bone scan tracer uptakes as metastatic or benign lesions using an artificial neural network; RELISTOR for opioid-induced constipation; and aPROMISE, an artificial intelligence medical device software; and PYLARIFY AI, an AI-based medical device software to perform quantitative assessment of PSMA PET/CT images in prostate cancer. In addition, it develops 1095, a PSMA-targeted iodine-131-labeled small molecule; PNT2002, a radiopharmaceutical therapy to treat mCRPC; PNT2003, an SSTR therapy that treats patients with SSTR-positive neuroendocrine tumors; MK-6240, a F 18-labeled PET imaging agent that targets Tau tangles in Alzheimer's disease; LNTH-1363S, an fibroblast activation protein, alpha targeted, copper-64 labeled PET imaging agent; and flurpiridaz used to assess blood flow to the heart;. It has collaboration agreements with GE Healthcare; NanoMab Technology Limited; Curium; RefleXion Medical, Inc.; POINT; Regeneron Pharmaceuticals, Inc; and Ratio Therapeutics LLC. The company was founded in 1956 and is based in Bedford, Massachusetts.Roivant Sciences NASDAQ:ROIV$18.22 +0.10 (+0.55%) Closing price 10/24/2025 04:00 PM EasternExtended Trading$18.22 0.00 (0.00%) As of 10/24/2025 07:11 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups. It develops VTAMA, a novel topical for the treatment of psoriasis and atopic dermatitis; batoclimab and IMVT-1402, the fully human monoclonal antibodies targeting the neonatal Fc receptor across various IgG-mediated autoimmune indications; and RVT-3101, an anti-TL1A antibody for ulcerative colitis and Crohn's disease. The company was founded in 2014 and is based in London, the United Kingdom. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 10/20 - 10/24 Freeport-McMoRan Posts Strong Earnings Despite Indonesia Shutdown Tesla’s Earnings Review: Does the Juice Justify the Squeeze? Warner Bros. Bidding War Potential: How High Could WBD Shares Go? Fal.Con Europe Could Be CrowdStrike’s Early Earnings Catalyst Logitech Eyes Breakout Before Earnings—Citigroup Sees 30% Upside Boeing Takes Off as FAA Greenlights 737 MAX Production Boost Capital One Just Flashed a Buy Signal—New Highs Could Be Next Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
